Archives
Humanized Mice Advance In Vivo–In Vitro Correlation of CES P
2026-04-12
Humanized Mice Advance In Vivo–In Vitro Correlation of CES Prodrugs
Study Background and Research Question
Neurodegenerative diseases such as Alzheimer's and Parkinson's present substantial clinical challenges due to limited treatment efficacy. Recent attention has focused on FK506 binding proteins (FKBPs) as neuroprotective drug targets. The compound HD561, a selective FKBP ligand, initially showed promise but underperformed in vivo due to poor pharmacokinetics. To address this, researchers developed HD56, a carboxylic acid ester prodrug designed to improve drug properties through enhanced metabolic stability and bioavailability. However, the translation of such prodrugs is complicated by pronounced species differences in carboxylesterase (CES) expression and activity, which can lead to misleading preclinical results. This study aimed to systematically assess the pharmacokinetic transformation of HD56 to its active form HD561 across species, and to evaluate the translational value of humanized liver mouse models for predicting human outcomes [source_type: paper][source_link: https://doi.org/10.1016/j.dmd.2025.100049].Key Innovation from the Reference Study
The pivotal innovation of this research lies in leveraging humanized liver mice—specifically, chimeric mice engrafted with human hepatocytes—to accurately model human-specific metabolism of the CES prodrug HD56. The study demonstrates that only in humanized mice does the in vitro–in vivo correlation (IVIVC) for prodrug conversion mirror human metabolic profiles, with a correlation coefficient of r = 0.98 [source_type: paper][source_link: https://doi.org/10.1016/j.dmd.2025.100049]. This establishes a new benchmark for preclinical testing of CES-metabolized prodrugs and provides a framework for rational drug design targeting human-specific metabolic pathways.Methods and Experimental Design Insights
The researchers adopted a multi-layered experimental approach:- Transport and Permeability Assays: Using Caco-2 and MDR1-overexpressing LLC-PK1 cell monolayers, they quantified the bidirectional transmembrane transport of both HD56 and HD561, establishing permeability differences between the prodrug and its active metabolite.
- Metabolic Phenotyping: Recombinant CES1 enzymes and chemical inhibition studies identified the primary metabolic pathways responsible for HD56 hydrolysis to HD561. CYP450 isoenzymes, notably CYP2C9, mediated further metabolism of HD561.
- Species Comparison: In vitro conversion rates were compared using hepatic/intestinal microsomes and plasma from humans, rats, monkeys, and humanized liver mice. In vivo pharmacokinetic (PK) studies mirrored these comparisons, with humanized mice stratified by engraftment level (Hu-URG, Hu-URG-Low, Hu-URG-High).
- IVIVC Analysis: Statistical correlation between in vitro hydrolysis rates and in vivo exposure levels was conducted across species.
Protocol Parameters
- assay: Caco-2 permeability | value_with_unit: HD56 Papp > HD561 (exact value not specified) | applicability: compound selection in prodrug design | rationale: Higher permeability improves oral bioavailability | source_type: paper [source_link: https://doi.org/10.1016/j.dmd.2025.100049]
- assay: In vitro hydrolysis (human liver microsomes) | value_with_unit: HD56 → HD561 conversion rate (quantitative values in supplementary) | applicability: metabolic stability assessment | rationale: Human CES1 is primary for HD56 activation | source_type: paper [source_link: https://doi.org/10.1016/j.dmd.2025.100049]
- assay: IVIVC (humanized mice) | value_with_unit: r = 0.98 | applicability: translation of preclinical PK data | rationale: Closest model to human metabolic fate | source_type: paper [source_link: https://doi.org/10.1016/j.dmd.2025.100049]
- assay: In vivo PK (humanized vs non-humanized mice) | value_with_unit: superior plasma exposure and conversion in humanized mice | applicability: model selection for prodrug evaluation | rationale: Humanized models minimize species bias | source_type: paper [source_link: https://doi.org/10.1016/j.dmd.2025.100049]
Core Findings and Why They Matter
The study reports several critical outcomes:- Permeability: HD56 displays higher membrane permeability than HD561, supporting the prodrug’s role in enhancing oral absorption.
- Metabolic Pathways: Hydrolysis of HD56 to HD561 is primarily catalyzed by CES1, with further metabolism of HD561 via CYP2C9.
- Species Differences: Significant interspecies variability exists in both the rate and tissue localization of HD56 hydrolysis. Only humanized mice accurately recapitulate human liver metabolism, while conventional rodent and primate models diverge considerably [source_type: paper][source_link: https://doi.org/10.1016/j.dmd.2025.100049].
- IVIVC Achieved: A high in vivo–in vitro correlation (r = 0.98) was observed exclusively in humanized mice, not in rats or monkeys, establishing these models as crucial for CES prodrug evaluation.
- Pharmacokinetic Superiority: Both in vitro and in vivo data support the conclusion that HD56’s PK properties surpass those of HD561, justifying prodrug strategies for CNS drug delivery.
Comparison with Existing Internal Articles
Recent internal literature on Oseltamivir acid, a well-established influenza neuraminidase inhibitor, provides a complementary perspective on prodrug metabolism and translational pharmacokinetics. For example, "Oseltamivir Acid: Mechanisms, Metabolism, and Next-Gen Insights" details the conversion of oseltamivir phosphate (a prodrug) to its active acid form, mirroring the HD56–HD561 paradigm. Both studies highlight the necessity of accurately modeling human-specific enzymatic pathways to predict clinical outcomes, particularly in the context of resistance mutations such as H275Y [source_type: internal_article][source_link: https://rox-azide-5-isomer.com/index.php?g=Wap&m=Article&a=detail&id=16219]. Similarly, "Oseltamivir Acid: Bridging Influenza Antiviral Research and Oncology" underscores the translational challenges posed by interspecies metabolic variability and the importance of robust IVIVC in drug development [source_type: internal_article][source_link: https://influenza-a-virus-fragment.com/index.php?g=Wap&m=Article&a=detail&id=85].Limitations and Transferability
While the use of humanized liver mice represents a significant advance, several limitations persist:- Model Complexity: Humanized mice, though superior, are resource-intensive and may not fully recapitulate all human metabolic nuances, especially extrahepatic metabolism.
- Data Generalizability: Findings pertain specifically to CES-metabolized prodrugs; extrapolation to other enzyme systems requires caution.
- Translational Gaps: The study does not address potential immunological or long-term toxicity outcomes associated with CES prodrug administration in humanized models.